FAQ type: - Tender Phase

In which situation is it foreseen that the ownership is transferred to the Buyers Group?

We believe that by developing the user interface and leveraging the already tested algorithm, we would be able to meet the requirements under use case number 9 (MDT decision support).
Nevertheless, further validation of the algorithm would be necessary and our main question is, if that could be done within INCAREHEART as part of the proposal?

On page 25 of the Challenge Brief, when talking about FR10.1 – “Incorporation of patient held devices”, you say: “In relation to devices for monitoring, suppliers will be required to consider innovations from the HSMonitor PCP.”.
Could you please specify which innovations you refer to? To our knowledge the results of HSMonitor are not in the public domain, are they?

Please clarify further in detail what you mean by: “The financial compensation for IPRs must reflect the market value of the benefits received (i.e., the opportunity that the IPRs offer for commercial exploitation) and the risks assumed by the contractor (e.g. the cost of maintaining IPRs and bringing the products onto the market)” page 40, section 4.4 TD1.
Does this concern the financial compensation that shall be given after the project 2024 to the regions involved in the project?

Since both of the two solutions will be piloted in all five procurers’ regions in Phase 3 of the project (FAQ 13), and possibly multiple sites at each region (FAQ 32) this also requires adopting the solution for all sites. Roughly this can be broken up into the following tasks

Technical integration with the specific systems (e.g. EHR) at each site. Developing, deciding, and describing the process and workflow at each site, including the content (text and other media) that should be served by the solution. Technically setting up the solution to fit process and content from 2. For each of these tasks, which party […]

On multiple questions we are asked to describe how “the proposed solution meets the requirements”. Since this is a procurement of R&D services, the degree to which the requirements are met will vary for our proposed solution considerably throughout the project time. So, to which point in time, or phase, should the description in the reply to the PCP apply in phase 1-3?

To what extent should the written report (abstract) in Phase 1 cover the objectives mentioned, i.e. technical, medical, financial and commercial?

If you receive a grant from EIT Accelerator, are you then disqualified from this procurement?

Considering NFR13.4, what are the available options for an integration with WINCARE EHR platform? Is there a Web API available or Web Services that would allow an interaction with WinCare? What would be the available data? What would be the data format (e.g. JSON, XML)?

As concerns FR10.1 “Incorporation of patient held devices”, it is stated that in relation to devices for monitoring, suppliers will be required to consider innovations from the HSMonitor PCP. We would like to ask if it will be enough to obtain information via the HSMonitor PCP websites and its relative sections where they briefly introduce the solutions that have been awarded so far for each Phase or if you will be able to provide us with more specific information or tools to gain other kind of access to it?